Post by OncoDaily

Can We Stop Lung Cancer Recurrence? Dr. Lee James, MD, PhD Explains Dr. Lee James, medical oncologist and leader of Medical Affairs at Eli Lilly and Company, discusses two of the most anticipated plenary presentations from American Society of Clinical Oncology (ASCO) 2026. He highlights the results of the LIBRETTO-432 Phase III trial, where selpercatinib (Retevmo) significantly reduced the risk of recurrence in patients with RET-positive non-small cell lung cancer following definitive treatment. Dr. James also reviews findings from the SARC041 study, which demonstrated promising benefits of abemaciclib in patients with metastatic dedifferentiated liposarcoma. Together, these studies showcase the growing impact of precision oncology, genomic profiling, and targeted therapies in improving outcomes for cancer patients. #ASOC2026 #ClinicalTrials #OncoDaily #Oncology #Cancer #Health #Medicine

Video Content